About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Global Viral Vector Manufacturing Market Size, CAGR of 19.7%, Forecast by 2031
Viral Vector Manufacturing Market

Viral Vector Manufacturing Market Size, Share & Trends Analysis Report By Type (Viral Vectors, Plasmid DNA), By Workflow (Upstream Manufacturing, Downstream Manufacturing), By Application (Gene Therapy, Vaccinology), By Disease (Cancer, Genetic Disorders, Infectious Diseases), By End User (Pharmaceutical and Biopharmaceutical Companies, Academics and Research Institutes, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI300DR
Last Updated : August 26, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Viral Vector Manufacturing Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Viral Vectors
        1. By Value
        2. Retroviruses
          1. Retroviruses By Value
        3. Adenoviruses
          1. Adenoviruses By Value
        4. Adeno-associated viruses (AAVs)
          1. Adeno-associated viruses (AAVs) By Value
        5. Lentiviruses
          1. Lentiviruses By Value
        6. Others
          1. Others By Value
      3. Plasmid DNA
        1. By Value
    3. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Upstream Manufacturing
        1. By Value
        2. Vector Amplification, Editing and Expansion
          1. Vector Amplification, Editing and Expansion By Value
        3. Vector Recovery/Harvesting
          1. Vector Recovery/Harvesting By Value
      3. Downstream Manufacturing
        1. By Value
        2. Purification
          1. Purification By Value
        3. Fill Finish
          1. Fill Finish By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Gene Therapy
        1. By Value
      3. Vaccinology
        1. By Value
    5. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Genetic Disorders
        1. By Value
      4. Infectious Diseases
        1. By Value
    6. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Academics and Research Institutes
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Viral Vectors
        1. By Value
        2. Retroviruses
          1. Retroviruses By Value
        3. Adenoviruses
          1. Adenoviruses By Value
        4. Adeno-associated viruses (AAVs)
          1. Adeno-associated viruses (AAVs) By Value
        5. Lentiviruses
          1. Lentiviruses By Value
        6. Others
          1. Others By Value
      3. Plasmid DNA
        1. By Value
    3. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Upstream Manufacturing
        1. By Value
        2. Vector Amplification, Editing and Expansion
          1. Vector Amplification, Editing and Expansion By Value
        3. Vector Recovery/Harvesting
          1. Vector Recovery/Harvesting By Value
      3. Downstream Manufacturing
        1. By Value
        2. Purification
          1. Purification By Value
        3. Fill Finish
          1. Fill Finish By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Gene Therapy
        1. By Value
      3. Vaccinology
        1. By Value
    5. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Genetic Disorders
        1. By Value
      4. Infectious Diseases
        1. By Value
    6. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Academics and Research Institutes
        1. By Value
      4. Others
        1. By Value
    7. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Viral Vectors
          1. By Value
          2. Retroviruses
            1. Retroviruses By Value
          3. Adenoviruses
            1. Adenoviruses By Value
          4. Adeno-associated viruses (AAVs)
            1. Adeno-associated viruses (AAVs) By Value
          5. Lentiviruses
            1. Lentiviruses By Value
          6. Others
            1. Others By Value
        3. Plasmid DNA
          1. By Value
      2. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Upstream Manufacturing
          1. By Value
          2. Vector Amplification, Editing and Expansion
            1. Vector Amplification, Editing and Expansion By Value
          3. Vector Recovery/Harvesting
            1. Vector Recovery/Harvesting By Value
        3. Downstream Manufacturing
          1. By Value
          2. Purification
            1. Purification By Value
          3. Fill Finish
            1. Fill Finish By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Gene Therapy
          1. By Value
        3. Vaccinology
          1. By Value
      4. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Genetic Disorders
          1. By Value
        4. Infectious Diseases
          1. By Value
      5. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Academics and Research Institutes
          1. By Value
        4. Others
          1. By Value
    8. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Viral Vectors
        1. By Value
        2. Retroviruses
          1. Retroviruses By Value
        3. Adenoviruses
          1. Adenoviruses By Value
        4. Adeno-associated viruses (AAVs)
          1. Adeno-associated viruses (AAVs) By Value
        5. Lentiviruses
          1. Lentiviruses By Value
        6. Others
          1. Others By Value
      3. Plasmid DNA
        1. By Value
    3. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Upstream Manufacturing
        1. By Value
        2. Vector Amplification, Editing and Expansion
          1. Vector Amplification, Editing and Expansion By Value
        3. Vector Recovery/Harvesting
          1. Vector Recovery/Harvesting By Value
      3. Downstream Manufacturing
        1. By Value
        2. Purification
          1. Purification By Value
        3. Fill Finish
          1. Fill Finish By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Gene Therapy
        1. By Value
      3. Vaccinology
        1. By Value
    5. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Genetic Disorders
        1. By Value
      4. Infectious Diseases
        1. By Value
    6. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Academics and Research Institutes
        1. By Value
      4. Others
        1. By Value
    7. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Viral Vectors
          1. By Value
          2. Retroviruses
            1. Retroviruses By Value
          3. Adenoviruses
            1. Adenoviruses By Value
          4. Adeno-associated viruses (AAVs)
            1. Adeno-associated viruses (AAVs) By Value
          5. Lentiviruses
            1. Lentiviruses By Value
          6. Others
            1. Others By Value
        3. Plasmid DNA
          1. By Value
      2. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Upstream Manufacturing
          1. By Value
          2. Vector Amplification, Editing and Expansion
            1. Vector Amplification, Editing and Expansion By Value
          3. Vector Recovery/Harvesting
            1. Vector Recovery/Harvesting By Value
        3. Downstream Manufacturing
          1. By Value
          2. Purification
            1. Purification By Value
          3. Fill Finish
            1. Fill Finish By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Gene Therapy
          1. By Value
        3. Vaccinology
          1. By Value
      4. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Genetic Disorders
          1. By Value
        4. Infectious Diseases
          1. By Value
      5. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Academics and Research Institutes
          1. By Value
        4. Others
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Viral Vectors
        1. By Value
        2. Retroviruses
          1. Retroviruses By Value
        3. Adenoviruses
          1. Adenoviruses By Value
        4. Adeno-associated viruses (AAVs)
          1. Adeno-associated viruses (AAVs) By Value
        5. Lentiviruses
          1. Lentiviruses By Value
        6. Others
          1. Others By Value
      3. Plasmid DNA
        1. By Value
    3. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Upstream Manufacturing
        1. By Value
        2. Vector Amplification, Editing and Expansion
          1. Vector Amplification, Editing and Expansion By Value
        3. Vector Recovery/Harvesting
          1. Vector Recovery/Harvesting By Value
      3. Downstream Manufacturing
        1. By Value
        2. Purification
          1. Purification By Value
        3. Fill Finish
          1. Fill Finish By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Gene Therapy
        1. By Value
      3. Vaccinology
        1. By Value
    5. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Genetic Disorders
        1. By Value
      4. Infectious Diseases
        1. By Value
    6. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Academics and Research Institutes
        1. By Value
      4. Others
        1. By Value
    7. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Viral Vectors
          1. By Value
          2. Retroviruses
            1. Retroviruses By Value
          3. Adenoviruses
            1. Adenoviruses By Value
          4. Adeno-associated viruses (AAVs)
            1. Adeno-associated viruses (AAVs) By Value
          5. Lentiviruses
            1. Lentiviruses By Value
          6. Others
            1. Others By Value
        3. Plasmid DNA
          1. By Value
      2. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Upstream Manufacturing
          1. By Value
          2. Vector Amplification, Editing and Expansion
            1. Vector Amplification, Editing and Expansion By Value
          3. Vector Recovery/Harvesting
            1. Vector Recovery/Harvesting By Value
        3. Downstream Manufacturing
          1. By Value
          2. Purification
            1. Purification By Value
          3. Fill Finish
            1. Fill Finish By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Gene Therapy
          1. By Value
        3. Vaccinology
          1. By Value
      4. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Genetic Disorders
          1. By Value
        4. Infectious Diseases
          1. By Value
      5. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Academics and Research Institutes
          1. By Value
        4. Others
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Viral Vectors
        1. By Value
        2. Retroviruses
          1. Retroviruses By Value
        3. Adenoviruses
          1. Adenoviruses By Value
        4. Adeno-associated viruses (AAVs)
          1. Adeno-associated viruses (AAVs) By Value
        5. Lentiviruses
          1. Lentiviruses By Value
        6. Others
          1. Others By Value
      3. Plasmid DNA
        1. By Value
    3. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Upstream Manufacturing
        1. By Value
        2. Vector Amplification, Editing and Expansion
          1. Vector Amplification, Editing and Expansion By Value
        3. Vector Recovery/Harvesting
          1. Vector Recovery/Harvesting By Value
      3. Downstream Manufacturing
        1. By Value
        2. Purification
          1. Purification By Value
        3. Fill Finish
          1. Fill Finish By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Gene Therapy
        1. By Value
      3. Vaccinology
        1. By Value
    5. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Genetic Disorders
        1. By Value
      4. Infectious Diseases
        1. By Value
    6. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Academics and Research Institutes
        1. By Value
      4. Others
        1. By Value
    7. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Viral Vectors
          1. By Value
          2. Retroviruses
            1. Retroviruses By Value
          3. Adenoviruses
            1. Adenoviruses By Value
          4. Adeno-associated viruses (AAVs)
            1. Adeno-associated viruses (AAVs) By Value
          5. Lentiviruses
            1. Lentiviruses By Value
          6. Others
            1. Others By Value
        3. Plasmid DNA
          1. By Value
      2. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Upstream Manufacturing
          1. By Value
          2. Vector Amplification, Editing and Expansion
            1. Vector Amplification, Editing and Expansion By Value
          3. Vector Recovery/Harvesting
            1. Vector Recovery/Harvesting By Value
        3. Downstream Manufacturing
          1. By Value
          2. Purification
            1. Purification By Value
          3. Fill Finish
            1. Fill Finish By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Gene Therapy
          1. By Value
        3. Vaccinology
          1. By Value
      4. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Genetic Disorders
          1. By Value
        4. Infectious Diseases
          1. By Value
      5. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Academics and Research Institutes
          1. By Value
        4. Others
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Viral Vectors
        1. By Value
        2. Retroviruses
          1. Retroviruses By Value
        3. Adenoviruses
          1. Adenoviruses By Value
        4. Adeno-associated viruses (AAVs)
          1. Adeno-associated viruses (AAVs) By Value
        5. Lentiviruses
          1. Lentiviruses By Value
        6. Others
          1. Others By Value
      3. Plasmid DNA
        1. By Value
    3. By Workflow
      1. Introduction
        1. Workflow By Value
      2. Upstream Manufacturing
        1. By Value
        2. Vector Amplification, Editing and Expansion
          1. Vector Amplification, Editing and Expansion By Value
        3. Vector Recovery/Harvesting
          1. Vector Recovery/Harvesting By Value
      3. Downstream Manufacturing
        1. By Value
        2. Purification
          1. Purification By Value
        3. Fill Finish
          1. Fill Finish By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Gene Therapy
        1. By Value
      3. Vaccinology
        1. By Value
    5. By Disease
      1. Introduction
        1. Disease By Value
      2. Cancer
        1. By Value
      3. Genetic Disorders
        1. By Value
      4. Infectious Diseases
        1. By Value
    6. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical and Biopharmaceutical Companies
        1. By Value
      3. Academics and Research Institutes
        1. By Value
      4. Others
        1. By Value
    7. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Viral Vectors
          1. By Value
          2. Retroviruses
            1. Retroviruses By Value
          3. Adenoviruses
            1. Adenoviruses By Value
          4. Adeno-associated viruses (AAVs)
            1. Adeno-associated viruses (AAVs) By Value
          5. Lentiviruses
            1. Lentiviruses By Value
          6. Others
            1. Others By Value
        3. Plasmid DNA
          1. By Value
      2. By Workflow
        1. Introduction
          1. Workflow By Value
        2. Upstream Manufacturing
          1. By Value
          2. Vector Amplification, Editing and Expansion
            1. Vector Amplification, Editing and Expansion By Value
          3. Vector Recovery/Harvesting
            1. Vector Recovery/Harvesting By Value
        3. Downstream Manufacturing
          1. By Value
          2. Purification
            1. Purification By Value
          3. Fill Finish
            1. Fill Finish By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Gene Therapy
          1. By Value
        3. Vaccinology
          1. By Value
      4. By Disease
        1. Introduction
          1. Disease By Value
        2. Cancer
          1. By Value
        3. Genetic Disorders
          1. By Value
        4. Infectious Diseases
          1. By Value
      5. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical and Biopharmaceutical Companies
          1. By Value
        3. Academics and Research Institutes
          1. By Value
        4. Others
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Viral Vector Manufacturing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Merck GA
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Lonza
    3. BD
    4. Fujifilm Diosynth biotechnologies USA Inc.
    5. Brammer Bio
    6. Cell Therapy Catapult Limited
    7. Waisman Biomanufacturing
    8. GENEZEN LABORATORIES
    9. Yposkesi Inc.
    10. REGENXBIO Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global digital manufacturing market size was valued at USD 387.65 billion in 2022 and is anticipated to reach USD 456 billion in 2023. It is expected to reach USD 1,670.45 billion by 2031, growing at a CAGR of 16.5% during the forecast perio
Buy Now
Global Report
Medical Component Manufacturing Market Size & Trends The global medical component manufacturing market size was valued at USD 15.34 billion in 2023. It is expected to reach USD 24.03 billion in 2032, growing at a CAGR of 5.1% over the forec
Buy Now
Global Report
The global smart manufacturing market size was valued at USD 283.23 billion in 2023. It is expected to reach USD 812.32 billion in 2032, growing at a CAGR of 12.42% over the forecast period (2024-2032). The adoption of Industry 4.0 technologies, incl
Buy Now
Global Report
The global viral vector plasmid DNA manufacturing market size was valued at USD 3.05 billion in 2022. It is estimated to reach USD 13.76 billion by 2031, growing at a CAGR of 18.2% during the forecast period (2023–2031). Viral vector
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.